Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

Peer Review reports

Original Submission
12 Jan 2022	Submitted	Original manuscript
17 Feb 2022	Reviewed	Reviewer Report - Kirsty Loudon
18 Mar 2022	Author responded	Author comments - Karen Hoang
Resubmission - Version 2
18 Mar 2022	Submitted	Manuscript version 2
Publishing
20 Mar 2022	Editorially accepted
1 Aug 2022	Article published	10.1186/s13063-022-06190-3

Back to article page